SCHEMBL428087

SCHEMBL428087

CN(C(=O)n1cnc(-c2ccc(S(=O)(=O)N3CCOCC3)cc2)c1)C1CCCCC1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.59
CES2 O00748 1/20 0.59
LMNA P02545 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
GAA P10253 3/20 0.46
IKBKB O14920 2/20 0.46
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 3/20 0.45
HPGD P15428 3/20 0.45
HSD17B10 Q99714 3/20 0.45
KMT2A Q03164 3/20 0.45
NPC1 O15118 1/20 0.45
MAPK1 P28482 1/20 0.45
RAB9A P51151 1/20 0.45
ATM Q13315 1/20 0.44
TSHR P16473 1/20 0.44
MEN1 O00255 1/20 0.43
GFER P55789 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL426108 0.89 FAAH (0.60) FAAHCES2LMNASMN1; SMN2GAA
SCHEMBL426096 0.84 FAAH (0.67) FAAHCES2SMN1; SMN2GAAALDH1A1
SCHEMBL426004 0.83 FAAH (0.66) FAAHCES2SMN1; SMN2GAAALDH1A1
SCHEMBL427259 0.81 FAAH (0.53) FAAHCES2LMNASMN1; SMN2GAA
SCHEMBL427723 0.79 FAAH (0.52) FAAHCES2SMN1; SMN2GAAALDH1A1
SCHEMBL425914 0.79 FAAH (0.66) FAAHCES2SMN1; SMN2ALDH1A1HPGD
SCHEMBL14950289 0.79 FAAH (0.66) FAAHCES2NPC1RAB9A
SCHEMBL425807 0.78 FAAH (0.65) FAAHCES2LMNAALDH1A1KDM4E
SCHEMBL425056 0.78 FAAH (0.65) FAAHCES2SMN1; SMN2ALDH1A1HPGD
SCHEMBL425811 0.78 FAAH (0.65) FAAHCES2HPGDKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885CES2 62/4885LMNA 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.